MedTrace Logo

Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients

NCT00761371 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2022-02-07

No results posted yet for this study

Summary

Imiquimod 5% cream in the treatment of external genital or perianal warts in HIV+ patients

Conditions

  • Warts

Interventions

DRUG

Imiquimod 5% cream

Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.

Sponsors & Collaborators

  • ORION Sante

    collaborator UNKNOWN

  • MEDA Pharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Philippe Saiag, MD, Prof. · Hospital Ambroise Pare, Department of Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2004-02-29
Completion
2004-02-29

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761371 on ClinicalTrials.gov